← All medications

Brimonidine

Medication alpha-2 agonist (ophthalmic) other
Aka: Alphagan
Brands seen in Singapore: Alphagan, Alphagan P, Brimochek, Rimonal, Combigan
Not medical advice. Check with your doctor or pharmacist before you start, stop or change the timing of anything you take.
How to use
What it’s for
Lowering eye pressure in glaucoma or ocular hypertension
When to take
SG label: one drop three times daily, about 8 h apart
Take with
Other eye drops spaced at least 5 minutes apart (SG label)
Pros & cons
Pros
  • SG label: for open-angle glaucoma or high eye pressure
  • FDA: can be used alongside other pressure drops
  • HSA: several brands registered, including generics
Cons
  • FDA: allergic, red or itchy eyes in 10–20% of people
  • FDA: dry mouth, tiredness and blurred vision
  • FDA: contraindicated under 2 years old
Sources
  1. HSA — Listing of Registered Therapeutic Products (data.gov.sg dataset d_767279312753558cbf19d48344577084), Forensicclassification column; 5,511 rows cached at /tmp/hsa_all.json and filtered locally, never re-fetched — 10 brimonidine rows · read 2026-08-27
    what it says
    “All 10 registered brimonidine products read "Prescription Only" — ALPHAGAN 0.2% SIN09788P, ALPHAGAN P 0.15% SIN12336P and 0.1% SIN17198P, BRIMOCHEK 0.2%, RIMONAL 0.15%, plus COMBIGAN, BRIMOCHEK-T, SIMBRINZA, GLAALPHA and MIRVASO gel.”
  2. MOH National Drug Formulary — ALPHAGAN P OPHTHALMIC SOLUTION 0.15% W/V [SIN12336P], Indications and Usage (SG package insert) · read 2026-08-27
    what it says
    “ALPHAGAN® P is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.”
  3. MOH National Drug Formulary — ALPHAGAN P 0.15% [SIN12336P], Dosage and Administration · read 2026-08-27
    what it says
    “The recommended dose is one drop of ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.15% in the affected eye(s) three times daily, approximately 8 hours apart … different drugs should be instilled at least 5 minutes apart.”
  4. MOH National Drug Formulary — ALPHAGAN P 0.15% [SIN12336P], Contraindications · read 2026-08-27
    what it says
    “ALPHAGAN® P is contraindicated in patients with hypersensitivity to brimonidine tartrate … also contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy and contraindicated in neonates and infants (children under the age of 2 years).”
  5. MOH National Drug Formulary — ALPHAGAN P 0.15% [SIN12336P], product information block · read 2026-08-27
    what it says
    “Forensic Classification: PRESCRIPTION ONLY MEDICINES · Anatomical Therapeutic Chemical (ATC) code S01EA05 · Prescription-only Medicines with Exemptions for Supply without Prescription: NA”
  6. US FDA label for ALPHAGAN P (brimonidine tartrate ophthalmic solution) 0.1%/0.15%, section 1, via openFDA drug/label.json (effective 2025-09-18) · read 2026-08-27
    what it says
    “ALPHAGAN P is an alpha adrenergic agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.”
  7. US FDA label for ALPHAGAN P, section 2 Dosage and Administration, via openFDA · read 2026-08-27
    what it says
    “The recommended dosage is one drop of ALPHAGAN P in the affected eye(s) three times daily, approximately 8 hours apart. ALPHAGAN P may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure.”
  8. US FDA label for ALPHAGAN P, section 4 Contraindications and 8.4 Pediatric Use, via openFDA · read 2026-08-27
    what it says
    “Neonates and Infants (Pediatric Patients Younger than 2 Years Old) … During postmarketing surveillance, apnea, bradycardia, coma, hypotension, hypothermia, hypotonia, lethargy, pallor, respiratory depression, and somnolence have been reported in infants receiving brimonidine.”
  9. US FDA label for ALPHAGAN P, section 5 Warnings and Precautions, via openFDA · read 2026-08-27
    what it says
    “ALPHAGAN P should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans … caution should be exercised in treating patients with severe cardiovascular disease.”
  10. US FDA label for ALPHAGAN P, section 6 Adverse Reactions, via openFDA · read 2026-08-27
    what it says
    “Most common adverse reactions occurring in approximately 5% to 20% of patients receiving brimonidine ophthalmic solution (0.1% to 0.2%) included allergic conjunctivitis, burning sensation, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, hypertension, ocular allergic reaction, oral dryness, and visual disturbance.”
  11. US FDA label for ALPHAGAN P, section 7 Drug Interactions, via openFDA · read 2026-08-27
    what it says
    “Antihypertensives/cardiac glycosides may lower blood pressure. Use with CNS depressants may result in an additive or potentiating effect. Tricyclic antidepressants may potentially blunt the hypotensive effect of systemic clonidine. Monoamine oxidase inhibitors may result in increased hypotension.”
Report a correction View as JSON

Updated 2026-08-29. Every line above traces to a numbered source. Kozen-X is not a medical device and does not give medical advice. It lists what published sources have written down — nothing more. A pair not listed is unrecorded, not cleared. Before you start, stop or re-time anything, talk to your doctor or pharmacist.